Exceedingly small iron oxide nanoparticles as positive MRI contrast agents
Standard
Exceedingly small iron oxide nanoparticles as positive MRI contrast agents. / Wei, He; Bruns, Oliver T; Kaul, Michael G; Hansen, Eric C; Barch, Mariya; Wiśniowska, Agata; Chen, Ou; Chen, Yue; Li, Nan; Okada, Satoshi; Cordero, Jose M; Heine, Markus; Farrar, Christian T; Montana, Daniel M; Adam, Gerhard; Ittrich, Harald; Jasanoff, Alan; Nielsen, Peter; Bawendi, Moungi G.
In: P NATL ACAD SCI USA, Vol. 114, No. 9, 28.02.2017, p. 2325-2330.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Exceedingly small iron oxide nanoparticles as positive MRI contrast agents
AU - Wei, He
AU - Bruns, Oliver T
AU - Kaul, Michael G
AU - Hansen, Eric C
AU - Barch, Mariya
AU - Wiśniowska, Agata
AU - Chen, Ou
AU - Chen, Yue
AU - Li, Nan
AU - Okada, Satoshi
AU - Cordero, Jose M
AU - Heine, Markus
AU - Farrar, Christian T
AU - Montana, Daniel M
AU - Adam, Gerhard
AU - Ittrich, Harald
AU - Jasanoff, Alan
AU - Nielsen, Peter
AU - Bawendi, Moungi G
PY - 2017/2/28
Y1 - 2017/2/28
N2 - Medical imaging is routine in the diagnosis and staging of a wide range of medical conditions. In particular, magnetic resonance imaging (MRI) is critical for visualizing soft tissue and organs, with over 60 million MRI procedures performed each year worldwide. About one-third of these procedures are contrast-enhanced MRI, and gadolinium-based contrast agents (GBCAs) are the mainstream MRI contrast agents used in the clinic. GBCAs have shown efficacy and are safe to use with most patients; however, some GBCAs have a small risk of adverse effects, including nephrogenic systemic fibrosis (NSF), the untreatable condition recently linked to gadolinium (Gd) exposure during MRI with contrast. In addition, Gd deposition in the human brain has been reported following contrast, and this is now under investigation by the US Food and Drug Administration (FDA). To address a perceived need for a Gd-free contrast agent with pharmacokinetic and imaging properties comparable to GBCAs, we have designed and developed zwitterion-coated exceedingly small superparamagnetic iron oxide nanoparticles (ZES-SPIONs) consisting of ∼3-nm inorganic cores and ∼1-nm ultrathin hydrophilic shell. These ZES-SPIONs are free of Gd and show a high T1 contrast power. We demonstrate the potential of ZES-SPIONs in preclinical MRI and magnetic resonance angiography.
AB - Medical imaging is routine in the diagnosis and staging of a wide range of medical conditions. In particular, magnetic resonance imaging (MRI) is critical for visualizing soft tissue and organs, with over 60 million MRI procedures performed each year worldwide. About one-third of these procedures are contrast-enhanced MRI, and gadolinium-based contrast agents (GBCAs) are the mainstream MRI contrast agents used in the clinic. GBCAs have shown efficacy and are safe to use with most patients; however, some GBCAs have a small risk of adverse effects, including nephrogenic systemic fibrosis (NSF), the untreatable condition recently linked to gadolinium (Gd) exposure during MRI with contrast. In addition, Gd deposition in the human brain has been reported following contrast, and this is now under investigation by the US Food and Drug Administration (FDA). To address a perceived need for a Gd-free contrast agent with pharmacokinetic and imaging properties comparable to GBCAs, we have designed and developed zwitterion-coated exceedingly small superparamagnetic iron oxide nanoparticles (ZES-SPIONs) consisting of ∼3-nm inorganic cores and ∼1-nm ultrathin hydrophilic shell. These ZES-SPIONs are free of Gd and show a high T1 contrast power. We demonstrate the potential of ZES-SPIONs in preclinical MRI and magnetic resonance angiography.
KW - Journal Article
U2 - 10.1073/pnas.1620145114
DO - 10.1073/pnas.1620145114
M3 - SCORING: Journal article
C2 - 28193901
VL - 114
SP - 2325
EP - 2330
JO - P NATL ACAD SCI USA
JF - P NATL ACAD SCI USA
SN - 0027-8424
IS - 9
ER -